Hancom Lifecare Discloses Corporate Governance Report: Lack of Dividends and Weak Governance Pose Investment Risks
Hancom Lifecare disclosed its corporate governance report as part of the business report as of May 28, 2026, detailing governance status and compliance with key indicators.
The largest shareholder is Hancom Inc. (36.13%), with minority shareholders holding 63.87%, indicating a high proportion of small investors.
Consolidated revenue decreased 12.1% YoY to 92,088 million KRW (2025), operating profit turned negative at -727 million KRW, and net loss was 7,665 million KRW.
No cash dividends were paid for the past three fiscal years (2023-2025) due to insufficient distributable profits, and no shareholder return policy is in place. No share buybacks or cancellations occurred.
Multiple non-compliances with governance key indicators: failure to announce general meeting 4 weeks in advance (only 2 weeks legally required), no dividend predictability, no dividend policy notification, no CEO succession plan, all-male board (lack of gender diversity), no cumulative voting, no policy to prevent appointment of persons responsible for corporate value damage, etc.
The board consists of 2 inside directors, 3 non-executive directors, and 4 outside directors (44.4% outside, meeting the legal minimum of 1/3). However, issues include no outside director as chair, no board committees, and lack of independence in audit support organization.
Internal audit body comprises one full-time and one part-time auditor, with no separate audit committee. The audit support team (planning/finance) is under management, limiting independence.
Communication with external auditor (EY Han Young) occurs at least quarterly, though some meetings are conducted in writing. The principle of holding meetings without management attendance is followed.
The company states it is focusing on business normalization due to poor performance and will review shareholder return policies when distributable profits become available. However, no specific timeline or targets are provided, reducing confidence in shareholder value enhancement.
[AI Comprehensive Analysis]Hancom Lifecare faces both poor earnings and weak governance, lacking short-term stock price catalysts. With no dividends or share buybacks, shareholder return expectations are low. While the company expresses intent to improve governance, the absence of concrete action plans limits its medium-to-long-term investment appeal.